Project Grant HT94252510504
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$660K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Framingham, MA 01702, USA
Similar Awards
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
The federal Project Grant award for $1,979,313.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the development of a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). The grant recipient, Sachi Bioworks, Inc., is a self-certified small disadvantaged business located in Erie, Colorado, that specializes in advanced biotechnology research and development. The funding will...
This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
This federal Project Grant award, valued at $680,591.00 and funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a novel small molecule screening approach to directly and selectively target repeat expansion RNA in C9ORF72 amyotrophic lateral sclerosis (ALS). The research is being conducted by Wayfinder Biosciences Inc., a for-profit organization located in Seattle, WA. The award period runs from June 15, 2025 to June 14, 2026....
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...
The federal Project Grant award in the amount of $925,757.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Wake Forest University Health Sciences (WFUHS) to selectively reduce repeat expansion RNA with small molecules to treat C9ORF72 mediated amyotrophic lateral sclerosis (ALS). The award, with a period of performance from April 1, 2025 to March 31, 2027, will enable WFUHS, a private non-profit academic...
This federal Project Grant award of $1,995,027.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, San Diego (UCSD) to develop therapy for C9ALS (chromosome 9 open reading frame 72-associated amyotrophic lateral sclerosis) using engineered RNA-targeting zinc finger proteins. The award, effective June 1, 2025 through May 31, 2028, will fund UCSD's specialized medical research and...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This $911,151 federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports the development of PEG10 inhibitors for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award was granted to the Regents of the University of Colorado, with a performance period from February 15, 2025 to February 14, 2027. The project aims to advance the scientific understanding and therapeutic...
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...